Crinetics Pharmaceuticals (CRNX) EBIT Margin (2017 - 2026)
Crinetics Pharmaceuticals (CRNX) posted quarterly EBIT Margin of 1307.79% for Q1 2026, up 2955232.0% year-over-year from N/an in Q1 2025, and up 39.72% quarter-over-quarter from 2169.55% in Q4 2025.
Powered by 
Analysis
Crinetics Pharmaceuticals (CRNX) EBIT Margin (2017 - 2026) Analysis & Trends
Crinetics Pharmaceuticals' EBIT Margin history runs 10 years deep, the most recent figure standing at 1307.79% for Q1 2026.
- In Q1 2026, EBIT Margin rose 2955232.0% year-over-year to 1307.79%; the TTM figure through Mar 2026 stood at 3020.32% (up 4654941.0% YoY), while the FY2025 annual figure was 6714.77%, up 2589870.0% from the prior year.
- EBIT Margin for Q1 2026 stood at 1307.79%, up from 2169.55% in the prior quarter.
- The five-year high for EBIT Margin was 1080.39% in Q1 2022, with the low at 99710.49% in Q3 2025.
- The 5-year median for EBIT Margin is 9646.51% (2022), against an average of 16434.89%.
- The sharpest annual moves came in 2025 and 2026: EBIT Margin plunged 1937120 bps in 2025, then soared 2955232 bps in 2026.
- Crinetics Pharmaceuticals' EBIT Margin stood at 6707.48% in 2022, then tumbled by 154 bps to 17045.38% in 2023, then decreased by 22 bps to 20747.62% in 2024, then jumped by 90 bps to 2169.55% in 2025, then jumped by 40 bps to 1307.79% in 2026.
- Business Quant data shows CRNX's EBIT Margin at 1307.79% in Q1 2026, 2169.55% in Q4 2025, and 99710.49% in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -562.07% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 19.06% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 17.93% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 19.75% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.36% |
| 10 | Crinetics Pharmaceuticals | 8.99 Bn | 8.99 Bn | 24.96 Mn | -527.35% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -527.35% |
| Mar 31, 2026 | -1,307.79% |
| Dec 31, 2025 | -2,169.55% |
| Sep 30, 2025 | -99,710.49% |
| Jun 30, 2025 | -12,522.99% |
| Mar 31, 2025 | -30,860.11% |
| Jun 30, 2024 | -20,747.62% |
| Mar 31, 2024 | -11,488.91% |
| Sep 30, 2023 | -17,045.38% |
| Jun 30, 2023 | -5,363.87% |
| Mar 31, 2023 | -1,790.89% |
| Dec 31, 2022 | -6,707.48% |
| Sep 30, 2022 | -9,487.77% |
| Jun 30, 2022 | -9,805.24% |
| Mar 31, 2022 | -1,080.39% |
| Dec 31, 2021 | -2,865.31% |
| Mar 31, 2020 | -25,045.07% |
| Dec 31, 2019 | -4,739.56% |
| Sep 30, 2019 | -3,015.64% |
| Mar 31, 2019 | -2,736.78% |